STOCK TITAN

electroCore to Announce Fourth Quarter and Year Ended December 31, 2020 Financial Results on Thursday, March 11

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Conference Call to be Held at 4:30pm Eastern Time

ROCKAWAY, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2020 after the close of the market on Thursday, March 11, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

Thursday, March 11 @ 4:30pm Eastern Time
Domestic:877-407-4018
International:201-689-8471
Conference ID:13715729
Webcast:http://public.viavid.com/index.php?id=143276

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients.

For more information, visit www.electrocore.com.

Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

or

Media Contact:
Summer Diaz
electroCore
973-290-0097
summer.diaz@electrocore.com


ElectroCore Inc

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Stock Data

Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
United States

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.